Thimble Point Acquisition Corp

Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The firm aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. It has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. The company’s lead product, reSET, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Its second product, reSET-O, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear's third product, Somryst for the treatment of chronic insomnia, was the first PDT submitted through the FDA's traditional 510(k) pathway while simultaneously reviewed through the FDA's Software Precertification Pilot Program. The company was founded on December 1, 2020 and is headquartered in Boston, MA.

The full company name is Sanswire Technologies Inc.

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium

Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

BOSTON & COLUMBIA, S.C.--(BUSINESS WIRE)--South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders

South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in Citi's 17th Annual BioPharma Conference

Pear Therapeutics to Participate in Citi's 17th Annual BioPharma Conference

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue.

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call.

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Reports Second Quarter 2022 Results

Pear Therapeutics Reports Second Quarter 2022 Results

BOSTON--(BUSINESS WIRE)--Pear Announces Publication of New Analysis of Real-World Data in Adults Using Somryst®

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Pear Therapeutics (PEAR)

BOSTON & SALT LAKE CITY--(BUSINESS WIRE)--Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized PDT for the Treatment of Opioid Use Disorder

Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

BOSTON--(BUSINESS WIRE)--Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to be Added to Russell US Index Series

Pear Therapeutics to be Added to Russell US Index Series

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference

Pear Therapeutics to Participate in the Cowen 7th Annual FutureHealth Conference

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Announces Three New Board Members

Pear Therapeutics Announces Three New Board Members

BOSTON--(BUSINESS WIRE)--Pear Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

BOSTON--(BUSINESS WIRE)--Pear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP

Pear Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst® at SLEEP 2022

BOSTON--(BUSINESS WIRE)--Pear Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Participate in the Jefferies Healthcare Conference

Pear Therapeutics to Participate in the Jefferies Healthcare Conference

Catalyst Biosciences

Endeavour Silver

Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch

BOSTON--(BUSINESS WIRE)--Pear Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Pear Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that.

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022

Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022

Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Michael Cherny - Bank of America Charles Rhyee - Cowen Neena Bitritto-Garg - Citi Eric Percher - Nephron Research Keay Nakae - Chardan Judah Frommer - Credit Suisse Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics First Quarter 2022 Earnings Conference Call.

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Pear Therapeutics Reports First Quarter 2022 Financial Results

News for Thimble Point Acquisition Corp Stock (PEAR)